Official Title
Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix
Brief Summary

Phase 1: 25 patients with a PCR-based diagnosis of Covid-19 will be be included to give 500 microliters of saliva and a 3 ml sample of blood for proteomic analysis; a drop of blood will also be put in a device connected to a silica matrix to perform spectrometric analyses. 25 patients with a non-Covid-19 respiratory infection will be included for the same samples. The proteomic analyses will be performed from classicaly draught blood, blood drop on silica, and saliva, to search for discriminating profiles between Covid-19 and non-Covid-19. Phase 2: 150 patients with a suspected Covid-19 will be included at the same time than the Covid-19PCR is performed ; they will have a sample of saliva and of a drop of blood for proteomic analysis, whose results will be matched with PCR results.

Detailed Description

Phase 1: derivation analyses 25 patients with a PCR-based diagnosis of Covid-19 will be be
included to give 500 microliters of saliva and a 3 ml sample of blood for proteomic analysis;
a drop of blood will also be put in a device connected to a silica matrix to perform
spectrometric analyses. 25 patients with a non-Covid-19 respiratory infection will be
included for the same samples. The proteomic analyses will be performed from classicaly
draught blood, blood drop on silica, and saliva, to search for discriminating profiles
between Covid-19 and non-Covid-19.

Phase 2: confirmation analyses 150 patients with a suspected Covid-19 will be included at the
same time than the Covid-19PCR is performed ; they will have a sample of saliva and of a drop
of blood for proteomic analysis, whose results will be matched with PCR results.

Unknown status
COVID19

Device: sample of blood and saliva

sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting

Eligibility Criteria

phase 1:

Inclusion Criteria for group 1:

- positive Covid-19 PCR

- clinical signs evocative of Covid-19

Exclusion Criteria for group 1:

- asymptomatic Covid-19 infection

Inclusion Criteria for group 1:

- negative Covid-19 PCR

- acute respiratory infection

Exclusion Criteria for group 1:

- none

Phase 2

Inclusion Criteria:

- suspicion of Covid-19

- sample for Covid-19 PCR planned or performed the same day

- admission ot emergency room exclusion criteria:

- past known Covid-19

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 99 Years
Countries
France
Locations

olivier EPAULARD
Grenoble, France

Investigator: olivier EPAULARD
Contact: 0033476765291
oepaulard@chu-grenoble.fr

University Hospital, Grenoble
NCT Number